-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is the original version of Translational Medicine.
Please indicate the source for reprinting
.
The research and development of new drugs is very costly and time-consuming, but it can sometimes be used to treat new diseases by changing the use of existing drugs.
However, a study found that "accepting the old drug-anti-malarial chloroquine for the treatment of new coronary pneumonia" experimental group Higher mortality rate! Research published on "Science Translational Medicine" on September 22 shows that experts say that drug reuse is not a shortcut to develop new treatments for diseases (including COVID-19), and there are inherent dangers and deficiencies , Not even an effective way to bring new drugs to the market
.
At present, there is no "magic bullet" for new coronary pneumonia, and there is a lack of rigorous clinical research, as well as the determination of the dosage and timetable for new indications
.
"New wine in old pots"-screening candidate new drugs from the old drugs for the new coronavirus infection that has swept the country, making an "old drug" debut in the war against the epidemic.
It is the drug of choice for anti-malaria- —Chloroquine
.
Chloroquine is an alkaline drug that increases the pH of the endosomes required for virus and cell fusion, inhibits virus reproduction and thereby inhibits virus infection
.
However, according to the latest seventh edition of the antiviral drugs of the new coronary pneumonia diagnosis and treatment plan, chloroquine is believed to be more effective than hydroxychloroquine against the new coronavirus, but the side effects of hydroxychloroquine are smaller and safer than chloroquine
.
Hydroxychloroquine can help zinc enter the cell, and zinc slows down the replication of the virus in the cell
.
After oral administration, the concentration in the lungs is 700 times higher than that in the serum, and hydroxychloroquine has human immunomodulatory activity, which is also its drug mechanism in prevention and early treatment.
.
The drug hydroxychloroquine Since chloroquine and hydroxychloroquine, two anti-malarial drugs, have entered the "old medicine and new use" to treat new coronary pneumonia, it has caused constant disturbances
.
Sweden, France and many other countries have stopped them to treat patients with new crown
.
Rick Bright, director of the U.
S.
Agency for Advanced Research and Development of Biomedicine, has also boycotted unproven antimalarial drugs to treat patients with COVID-19
.
In terms of clinical research, Brazilian researchers stopped some hydroxychloroquine research because some patients experienced heart rhythm problems after receiving two high-dose drugs
.
The U.
S.
Veterans Health Administration Medical Center conducted a study and found that the experimental group receiving hydroxychloroquine for the treatment of new coronary pneumonia had a higher mortality rate! According to the case reports in the FDA's adverse event reporting system database, hydroxychloroquine has only been approved by the FDA to enter the phase 3 clinical trial of COVID-19, and the FDA has not approved chloroquine and hydroxychloroquine for the treatment and prevention of COVID-19.
It is expected to recruit 200,000 people in the future.
Patients participated in more than 100 studies on hydroxychloroquine
.
The results of the clinical data study of the new crown "magic drug" Redcivir are also unsatisfactory
.
WHO Director-General Tedros Adhanom Ghebreyesus pointed out that there is currently no "magic bullet" for COVID-19, and there may never be one
.
During the pandemic, all countries hope to find effective drugs, but for drugs, experiments, specific scientific laws and rigorous logic are needed to prove that they are safe and effective.
Political public opinion cannot be a lever to influence science.
Research on specific drugs , Need to wait
.
The development of SARS-CoV-2 therapeutic drugs faces challenges and opportunities.
Experts said that drug reuse is not a shortcut to develop new disease treatments (including the new crown virus).
The use of chloroquine, hydroxychloroquine, ivermectin and other similar compounds There are inherent dangers and shortcomings in drugs that are converted to treat the new coronavirus
.
A paper written by Australian drug discovery and translation experts (including the pharmaceutical industry, academia, and investors) highlights the potential challenges and opportunities for drug reuse
.
Researchers published an article titled "Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers" on September 22 in "Science Translational Medicine.
" The potential methods of new treatments for the new coronavirus have become the focus of global attention
.
DOI: 10.
1126/scitranslmed.
abd5524 Although there is a hypothesis that drug reuse is an effective way to bring new drugs to the market, the lead author of the study and the former global leader and associate of hematology/oncology research in Amgen, California Dr.
Glenn Begley, president and current co-founder of Boston Parthenon Therapy, believes that there are only a few examples of academic groups that have successfully changed the use of drugs
.
Dr.
Begley said that the regulatory process still requires a clear commercial value proposition, clear intellectual property rights, established understanding of drug metabolism, and rigorous preclinical and clinical studies to determine the dosage and schedule for new indications
.
He cited an example of reusing the controversial and failed drug thalidomide to treat leprosy and multiple myeloma, which is a long process
.
Other measures include reusing the veterinary anti-helminth drug Moximectin to treat river blindness, and the use of the fungicide dimethyl fumarate for the treatment of relapsing multiple sclerosis
.
Dr.
Begley said: "Reuse of drugs is rarely as trivial as taking approved drugs and using the same dosage and dosing schedule for clinical trials in different diseases
.
"This requires new preclinical safety and effectiveness studies, appropriately designed phase I and phase II studies, supervision by regulatory agencies, and the establishment of new intellectual property rights
.
The failure rate, cost, and time are similar to those of new drug development
.
This is not a stopgap
.
"In addition, if these key issues are not solved, many clinical projects for drug reuse cannot meet the'clinical equilibrium', so it is unethical
.
"The co-author of this study, a well-known medicinal chemist, Professor Jonathan Baell of Monash University, said: "There is a hypothesis that drug reuse is an effective way to bring new drugs to the market
.
In fact, this is naive, ignoring the reality that many drug developments require regulatory approval
.
"Professor Baell said that more than 100 drug reuse projects are currently underway to develop new treatments for the new coronavirus, including anti-infective drugs such as remdesivir, chloroquine, ivermectin and hydroxychloroquine
.
But because There is no clear randomized controlled phase 3 clinical trial to help determine its effectiveness in different environments, and early reports on its effectiveness are mixed
.
He pointed out: “One of the main challenges faced by some of the efforts to reuse drugs is that, Failure to link the way the drug moves in the body or how the body responds to the drug at the concentration required to treat the new coronavirus
.
"Professor Baell said that more research is underway to identify drugs that may be re-used to treat the new coronavirus , but many compounds lack efficacy, require very high doses, and may not be tolerated in order to be clinically beneficial
.
UniQuest implementation Director, commercialization and research co-author Dr.
Mark Ashton said: "One of the most common challenges of drug reuse is the lack of expertise to drive development and commercialization.
.
We cannot expect those with unquestionable expertise in basic science and clinical medicine to have the expertise needed to successfully navigate intellectual property, preclinical and clinical development, and regulatory and reimbursement requirements for potential drug candidates
.
"In this regard, university technology transfer offices or commercial and industrial experts, as well as strengthening the supervision and identification of drug reuse opportunities, can really help
.
"References: 1.
https://medicalxpress.
com/news/2021-09-drug-repurposing-panacea-covid-.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
If you need to get health For guidance, please go to a regular hospital for treatment
.
Popular·Article Gene Sequencing [Hot Discussion] How to achieve more uniform and accurate genetic testing? Shock! Two top genetic testing companies performed liquid biopsies on the same group of cancer patients, and the results were quite different.
The new coronavirus [Nature Hot Discussion] The new coronavirus is getting more and more powerful, but the protective efficacy of the vaccine is gradually weakening.
What should we do? New Coronavirus [Nature Hot Discussion] The epidemic in Fujian has spread to four places! Israel’s 1.
1 million large-scale study: The vaccinated booster shot is 19.
5 times less likely to be infected with the new crown than people who have only received two injections.
[Science] Nearly 500 million people live in areas where the coronavirus may overflow.
The new crown is just the tip of the iceberg.
There will be more SARS-like viruses! Gut Microorganism [Genome Medicine] is the first to use gut microbial data for the prognosis study of rheumatoid arthritis, which is expected to become the key to future treatment! Organoid Research [Nature Sub-Journal] The use of synthetic new gels can easily cultivate pancreatic "organoids" and accurately replicate human pancreatic tumor research [The Lancet] Low-dose CT screening for lung cancer can really effectively reduce mortality NS? British scientists will show you the answer through experiments! New crown virus [heavy weight] How protective is the new crown vaccine against delta virus? The US Centers for Disease Control and Prevention has given the answer: The death rate of the unvaccinated population is 11 times that of the vaccinated population! Gene Sequencing [Nature Sub-Journal] The largest DNAm gene study to date: the study of genetic mutations related to DNAm at 420,509 DNAm loci in the blood has been identified.
[Heavyweight] Johns Hopkins University scientists have discovered genetic The self-correction function can resist blood cancer, which is expected to be a major breakthrough in the treatment of blood cancer! Genetic testing [Nature Sub-Journal] The 1.
5 million largest genome-wide association study has identified nearly 600 gene loci related to anti-social behavior, alcoholism, and opioid addiction.
The new coronavirus [Nature] is a heavyweight! Why can the delta mutant virus spread so quickly and fiercely? Scientists from the University of Cambridge take you to learn about its recommendations and activities The 3rd Shanghai International Cancer Conference The 5th Symposium on Modern Clinical Molecular Diagnosis
Please indicate the source for reprinting
.
The research and development of new drugs is very costly and time-consuming, but it can sometimes be used to treat new diseases by changing the use of existing drugs.
However, a study found that "accepting the old drug-anti-malarial chloroquine for the treatment of new coronary pneumonia" experimental group Higher mortality rate! Research published on "Science Translational Medicine" on September 22 shows that experts say that drug reuse is not a shortcut to develop new treatments for diseases (including COVID-19), and there are inherent dangers and deficiencies , Not even an effective way to bring new drugs to the market
.
At present, there is no "magic bullet" for new coronary pneumonia, and there is a lack of rigorous clinical research, as well as the determination of the dosage and timetable for new indications
.
"New wine in old pots"-screening candidate new drugs from the old drugs for the new coronavirus infection that has swept the country, making an "old drug" debut in the war against the epidemic.
It is the drug of choice for anti-malaria- —Chloroquine
.
Chloroquine is an alkaline drug that increases the pH of the endosomes required for virus and cell fusion, inhibits virus reproduction and thereby inhibits virus infection
.
However, according to the latest seventh edition of the antiviral drugs of the new coronary pneumonia diagnosis and treatment plan, chloroquine is believed to be more effective than hydroxychloroquine against the new coronavirus, but the side effects of hydroxychloroquine are smaller and safer than chloroquine
.
Hydroxychloroquine can help zinc enter the cell, and zinc slows down the replication of the virus in the cell
.
After oral administration, the concentration in the lungs is 700 times higher than that in the serum, and hydroxychloroquine has human immunomodulatory activity, which is also its drug mechanism in prevention and early treatment.
.
The drug hydroxychloroquine Since chloroquine and hydroxychloroquine, two anti-malarial drugs, have entered the "old medicine and new use" to treat new coronary pneumonia, it has caused constant disturbances
.
Sweden, France and many other countries have stopped them to treat patients with new crown
.
Rick Bright, director of the U.
S.
Agency for Advanced Research and Development of Biomedicine, has also boycotted unproven antimalarial drugs to treat patients with COVID-19
.
In terms of clinical research, Brazilian researchers stopped some hydroxychloroquine research because some patients experienced heart rhythm problems after receiving two high-dose drugs
.
The U.
S.
Veterans Health Administration Medical Center conducted a study and found that the experimental group receiving hydroxychloroquine for the treatment of new coronary pneumonia had a higher mortality rate! According to the case reports in the FDA's adverse event reporting system database, hydroxychloroquine has only been approved by the FDA to enter the phase 3 clinical trial of COVID-19, and the FDA has not approved chloroquine and hydroxychloroquine for the treatment and prevention of COVID-19.
It is expected to recruit 200,000 people in the future.
Patients participated in more than 100 studies on hydroxychloroquine
.
The results of the clinical data study of the new crown "magic drug" Redcivir are also unsatisfactory
.
WHO Director-General Tedros Adhanom Ghebreyesus pointed out that there is currently no "magic bullet" for COVID-19, and there may never be one
.
During the pandemic, all countries hope to find effective drugs, but for drugs, experiments, specific scientific laws and rigorous logic are needed to prove that they are safe and effective.
Political public opinion cannot be a lever to influence science.
Research on specific drugs , Need to wait
.
The development of SARS-CoV-2 therapeutic drugs faces challenges and opportunities.
Experts said that drug reuse is not a shortcut to develop new disease treatments (including the new crown virus).
The use of chloroquine, hydroxychloroquine, ivermectin and other similar compounds There are inherent dangers and shortcomings in drugs that are converted to treat the new coronavirus
.
A paper written by Australian drug discovery and translation experts (including the pharmaceutical industry, academia, and investors) highlights the potential challenges and opportunities for drug reuse
.
Researchers published an article titled "Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers" on September 22 in "Science Translational Medicine.
" The potential methods of new treatments for the new coronavirus have become the focus of global attention
.
DOI: 10.
1126/scitranslmed.
abd5524 Although there is a hypothesis that drug reuse is an effective way to bring new drugs to the market, the lead author of the study and the former global leader and associate of hematology/oncology research in Amgen, California Dr.
Glenn Begley, president and current co-founder of Boston Parthenon Therapy, believes that there are only a few examples of academic groups that have successfully changed the use of drugs
.
Dr.
Begley said that the regulatory process still requires a clear commercial value proposition, clear intellectual property rights, established understanding of drug metabolism, and rigorous preclinical and clinical studies to determine the dosage and schedule for new indications
.
He cited an example of reusing the controversial and failed drug thalidomide to treat leprosy and multiple myeloma, which is a long process
.
Other measures include reusing the veterinary anti-helminth drug Moximectin to treat river blindness, and the use of the fungicide dimethyl fumarate for the treatment of relapsing multiple sclerosis
.
Dr.
Begley said: "Reuse of drugs is rarely as trivial as taking approved drugs and using the same dosage and dosing schedule for clinical trials in different diseases
.
"This requires new preclinical safety and effectiveness studies, appropriately designed phase I and phase II studies, supervision by regulatory agencies, and the establishment of new intellectual property rights
.
The failure rate, cost, and time are similar to those of new drug development
.
This is not a stopgap
.
"In addition, if these key issues are not solved, many clinical projects for drug reuse cannot meet the'clinical equilibrium', so it is unethical
.
"The co-author of this study, a well-known medicinal chemist, Professor Jonathan Baell of Monash University, said: "There is a hypothesis that drug reuse is an effective way to bring new drugs to the market
.
In fact, this is naive, ignoring the reality that many drug developments require regulatory approval
.
"Professor Baell said that more than 100 drug reuse projects are currently underway to develop new treatments for the new coronavirus, including anti-infective drugs such as remdesivir, chloroquine, ivermectin and hydroxychloroquine
.
But because There is no clear randomized controlled phase 3 clinical trial to help determine its effectiveness in different environments, and early reports on its effectiveness are mixed
.
He pointed out: “One of the main challenges faced by some of the efforts to reuse drugs is that, Failure to link the way the drug moves in the body or how the body responds to the drug at the concentration required to treat the new coronavirus
.
"Professor Baell said that more research is underway to identify drugs that may be re-used to treat the new coronavirus , but many compounds lack efficacy, require very high doses, and may not be tolerated in order to be clinically beneficial
.
UniQuest implementation Director, commercialization and research co-author Dr.
Mark Ashton said: "One of the most common challenges of drug reuse is the lack of expertise to drive development and commercialization.
.
We cannot expect those with unquestionable expertise in basic science and clinical medicine to have the expertise needed to successfully navigate intellectual property, preclinical and clinical development, and regulatory and reimbursement requirements for potential drug candidates
.
"In this regard, university technology transfer offices or commercial and industrial experts, as well as strengthening the supervision and identification of drug reuse opportunities, can really help
.
"References: 1.
https://medicalxpress.
com/news/2021-09-drug-repurposing-panacea-covid-.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
.
If you need to get health For guidance, please go to a regular hospital for treatment
.
Popular·Article Gene Sequencing [Hot Discussion] How to achieve more uniform and accurate genetic testing? Shock! Two top genetic testing companies performed liquid biopsies on the same group of cancer patients, and the results were quite different.
The new coronavirus [Nature Hot Discussion] The new coronavirus is getting more and more powerful, but the protective efficacy of the vaccine is gradually weakening.
What should we do? New Coronavirus [Nature Hot Discussion] The epidemic in Fujian has spread to four places! Israel’s 1.
1 million large-scale study: The vaccinated booster shot is 19.
5 times less likely to be infected with the new crown than people who have only received two injections.
[Science] Nearly 500 million people live in areas where the coronavirus may overflow.
The new crown is just the tip of the iceberg.
There will be more SARS-like viruses! Gut Microorganism [Genome Medicine] is the first to use gut microbial data for the prognosis study of rheumatoid arthritis, which is expected to become the key to future treatment! Organoid Research [Nature Sub-Journal] The use of synthetic new gels can easily cultivate pancreatic "organoids" and accurately replicate human pancreatic tumor research [The Lancet] Low-dose CT screening for lung cancer can really effectively reduce mortality NS? British scientists will show you the answer through experiments! New crown virus [heavy weight] How protective is the new crown vaccine against delta virus? The US Centers for Disease Control and Prevention has given the answer: The death rate of the unvaccinated population is 11 times that of the vaccinated population! Gene Sequencing [Nature Sub-Journal] The largest DNAm gene study to date: the study of genetic mutations related to DNAm at 420,509 DNAm loci in the blood has been identified.
[Heavyweight] Johns Hopkins University scientists have discovered genetic The self-correction function can resist blood cancer, which is expected to be a major breakthrough in the treatment of blood cancer! Genetic testing [Nature Sub-Journal] The 1.
5 million largest genome-wide association study has identified nearly 600 gene loci related to anti-social behavior, alcoholism, and opioid addiction.
The new coronavirus [Nature] is a heavyweight! Why can the delta mutant virus spread so quickly and fiercely? Scientists from the University of Cambridge take you to learn about its recommendations and activities The 3rd Shanghai International Cancer Conference The 5th Symposium on Modern Clinical Molecular Diagnosis
